News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
careplusvn.com Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medicalยฎ Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. โฆ
Envoy Medical (NASDAQ: COCH) reported its Q2 2026 financial results, including a net loss of $7.3 million and net revenue of $51,000. The company significantly increased its cash position to $19.7 million from $3.7 million at year-end 2025, supported by $30 million in equity โฆ
Envoy Medical reported its second quarter 2026 financial results, highlighting significant progress in its corporate initiatives, particularly with its investigational Acclaimยฎ cochlear implant. The company submitted the first module of its modular PMA application to the FDA and announced positive 12-month data from its โฆ
Lucid Capital Markets has initiated coverage on Envoy Medical (NASDAQ:COCH) with a buy rating and a price target of $2.00, representing a 203% upside. The firm highlighted Envoyโs fully implanted cochlear implant device, Acclaim, which offers 24/7 hearing without external components and has received โฆ
Envoy Medical has reached a significant milestone, surpassing the three-month mark for all 56 patients in its pivotal clinical trial for the Acclaim cochlear implant. The company is on track for FDA submission and anticipates achieving six-month and twelve-month visit milestones by late 2026 โฆ
Envoy Medical (NASDAQ: COCH) announced that all 56 patients in its pivotal clinical trial for the investigational Acclaim cochlear implant have completed their three-month visit milestone. This achievement is a crucial step toward the company's planned Premarket Approval (PMA) submission to the U.S. FDA. โฆ
Envoy Medical Inc. announced that all 56 patients in its pivotal clinical trial for the investigational fully implanted Acclaimยฎ cochlear implant have surpassed the three-month visit milestone. This achievement brings the company closer to submitting its Premarket Approval application to the FDA for the โฆ
Envoy Medical Inc. reported improved 12-month results from Stage 1 of its pivotal clinical trial for the Acclaim cochlear implant, showing a significant increase in hearing performance compared to baseline and six-month data. Participants achieved a mean CNC word recognition score of 53.2% at โฆ
H.C. Wainwright has reiterated a Buy rating and a $2.50 price target for Envoy Medical (NASDAQ:COCH) after an update on the pivotal trial of its Acclaim cochlear implant. The company announced that the first three patients have completed their 12-month endpoint visits, with topline โฆ
Envoy Medical announced positive 12-month data from Stage 1 of its pivotal clinical trial for the Acclaimยฎ fully implanted cochlear implant, showing significant improvements in speech perception. The study's first 10 participants demonstrated a substantial increase in CNC word recognition scores, with continued improvement โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States